Moderna (MRNA) Revenue & Revenue Breakdown
Moderna Revenue Highlights
Latest Revenue (Y)
$6.85B
Latest Revenue (Q)
$1.86B
Main Segment (Y)
Product Sales
Main Geography (Y)
Rest Of The World
Moderna Revenue by Period
Moderna Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $6.85B | -64.45% |
| 2022-12-31 | $19.26B | 8.61% |
| 2021-12-31 | $17.74B | 6361.44% |
| 2020-12-31 | $274.49M | 471.43% |
| 2019-12-31 | $48.04M | -60.79% |
| 2018-12-31 | $122.51M | -30.77% |
| 2017-12-31 | $176.97M | 74.30% |
| 2016-12-31 | $101.54M | - |
Moderna generated $6.85B in revenue during NA 2023, up -64.45% compared to the previous quarter, and up 5589.66% compared to the same period a year ago.
Moderna Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $1.86B | 672.61% |
| 2024-06-30 | $241.00M | 44.31% |
| 2024-03-31 | $167.00M | -94.06% |
| 2023-12-31 | $2.81B | 53.63% |
| 2023-09-30 | $1.83B | 432.27% |
| 2023-06-30 | $344.00M | -81.53% |
| 2023-03-31 | $1.86B | -63.38% |
| 2022-12-31 | $5.08B | 57.89% |
| 2022-09-30 | $3.22B | -29.48% |
| 2022-06-30 | $4.57B | -23.13% |
| 2022-03-31 | $5.94B | -14.52% |
| 2021-12-31 | $6.95B | 43.90% |
| 2021-09-30 | $4.83B | 14.57% |
| 2021-06-30 | $4.21B | 141.82% |
| 2021-03-31 | $1.74B | 659.89% |
| 2020-12-31 | $229.38M | 1777.66% |
| 2020-09-30 | $12.22M | -57.05% |
| 2020-06-30 | $28.44M | 538.14% |
| 2020-03-31 | $4.46M | -57.77% |
| 2019-12-31 | $10.55M | -20.88% |
| 2019-09-30 | $13.34M | 32.98% |
| 2019-06-30 | $10.03M | -28.94% |
| 2019-03-31 | $14.12M | -56.99% |
| 2018-12-31 | $32.82M | -10.49% |
| 2018-09-30 | $36.66M | 41.93% |
| 2018-06-30 | $25.83M | -5.93% |
| 2018-03-31 | $27.46M | -68.94% |
| 2017-12-31 | $88.42M | 108.17% |
| 2017-09-30 | $42.47M | 18.89% |
| 2017-06-30 | $35.72M | - |
| 2017-03-31 | $35.72M | - |
Moderna generated $1.86B in revenue during Q3 2024, up 672.61% compared to the previous quarter, and up 541.28% compared to the same period a year ago.
Moderna Revenue Breakdown
Moderna Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Grant | $94.00M | $388.00M | $735.00M | $528.90M | $12.17M |
| Product Sales | $8.20B | $3.88B | - | - | - |
| Collaboration Arrangement | $31.00M | $440.00M | $61.00M | $74.62M | - |
| Collaboration Arrangement Including Arrangements With Affiliate | - | - | - | $327.70M | - |
| Collaborative Arrangement With Related Party | - | - | - | - | $5.23M |
Moderna's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product Sales (98.50%), Grant (1.13%), and Collaboration Arrangement (0.37%).
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant | $8.00M | $20.00M | - | $50.00M | $44.00M | $-65.00M | $144.00M | $183.00M | $126.00M | $262.00M | $140.00M | $139.00M | $194.00M | $341.37M | $3.93M | $3.50M | - | - | - | - |
| Product Sales | $2.96B | $645.00M | $522.00M | $3.58B | $2.42B | $1.00B | $1.20B | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration Arrangement | $7.00M | $6.00M | $3.00M | $12.00M | $19.00M | $290.00M | $100.00M | $35.00M | $15.00M | $14.00M | $19.00M | $18.00M | $10.00M | $29.50M | $10.05M | - | - | - | - | - |
| Collaboration Arrangement Including Arrangements With Affiliate | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $29.50M | - | - | - | - |
| Collaboration Arrangement, Including Arrangements With Affiliate | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $366.70M | $249.90M | $4.46M | - |
| Collaborative Arrangement With Related Party | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.27M | - |
Moderna's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product Sales (99.50%), Grant (0.27%), and Collaboration Arrangement (0.23%).
Moderna Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Rest Of The World | $3.60B | - | - | - |
| Europe | $1.35B | $6.73B | $6.83B | - |
| UNITED STATES | $1.90B | $4.41B | $5.39B | $193.63M |
| Rest Of World | - | $7.30B | $5.45B | - |
| Non-US | - | - | - | $6.24M |
Moderna's latest annual revenue breakdown by geography, as of Dec 23: Rest Of The World (52.54%), UNITED STATES (27.67%), and Europe (19.79%).
Quarterly Revenue by Country
| Country | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rest Of The World | $324.00M | $22.00M | $67.00M | $1.38B | $741.00M | $231.00M | $1.25B | $1.09B | $1.69B | $2.90B | - | - | - | - | - |
| UNITED STATES | $1.22B | $162.00M | $100.00M | $979.00M | $913.00M | $2.00M | $1.00M | $1.02B | $985.00M | $1.45B | $945.00M | $745.00M | $1.20B | $2.09B | $1.36B |
| Europe | $281.00M | - | - | $616.00M | $103.00M | $60.00M | $576.00M | $2.22B | $1.04B | $1.39B | $2.08B | - | - | - | - |
| Non-US | - | - | - | - | - | - | - | - | - | - | - | - | $3.61B | $2.10B | $375.00M |
Moderna's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (66.76%), Rest Of The World (17.80%), and Europe (15.44%).
Moderna Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | $9.84B | $2.77B |
| MRNA | Moderna | $6.85B | $1.86B |
| NVAX | Novavax | $983.71M | $415.48M |
| BEAM | Beam Therapeutics | $377.71M | $14.27M |
| DNA | Ginkgo Bioworks | $251.46M | $89.05M |
| CVAC | CureVac | $52.70M | $12.37M |
| KRYS | Krystal Biotech | $50.70M | $83.84M |
| NTLA | Intellia Therapeutics | $36.27M | $9.11M |
| EDIT | Editas Medicine | - | - |
| ELEV | Elevation Oncology | - | - |
| OCEA | Ocean Biomedical | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| ENVB | Enveric Biosciences | - | - |